N/A
Completed N=99
Increasing Breast Cancer Screening in Chinese Immigrants
Screening Mammogram
Source: ClinicalTrials.gov NCT05089292 ↗
Enrolled (actual)
99
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcomePrimary: Number of Participants That Scored Above 80% in the Feasibility and Acceptability Questionnaire — 99 Participants
Summary
The long-term goal of this research is to increase breast cancer screening rates in NYC Chinese immigrants. The researchers plan to accomplish this objective by developing and testing a culturally- and linguistically-adapted Witness Project program for Chinese immigrants. To inform the intervention development, the study team will identify barriers and facilitators to breast cancer screening in Chinese immigrants through individual qualitative interviews.
A total of 156 participants will be recruited during the entire study.
In Aim 1 which started in July 2021, 60 women were recruited for in-depth interviews to assess their breast cancer knowledge, perceived barriers and benefits/risks to completing mammography, perceived susceptibility to breast cancer, fatalism, screening intention, acculturation, language preference, and health literacy.
In Aim 2, 96 women will be recruited to participate in the pilot testing of the intervention. Recruitment will take place at community sites that serve Chinese immigrants in New York City. Enrollment for Aim 2 is anticipated to start in March of 2022.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants That Scored Above 80% in the Feasibility and Acceptability Questionnaire |
99 | — |
| PRIMARY Number of Participants Who Were Engaged in Program |
99 | — |
| PRIMARY Percentage of Community Organizations Willing to Host Program |
22 | — |
| SECONDARY Change in Breast Cancer Knowledge |
4.33; 4.89 | — |
Eligibility Criteria
Inclusion Criteria
- ≥ 40 years of age
- female
- born in China
- read and speak Cantonese, Mandarin, or English
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT05089292). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.